Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Clover Health Investments (CLOV) filed its Q3 2025 10‑Q, reporting higher revenue but a wider loss. Total revenues were $496.7 million for the quarter, up from $331.0 million a year ago, driven primarily by higher premiums earned. Net loss from continuing operations was $24.4 million, compared with $8.8 million in the prior-year quarter, as net medical claims and operating costs increased with membership activity.
For the nine months ended September 30, 2025, revenue reached $1.44 billion and net loss from continuing operations was $36.2 million. Cash and cash equivalents were $190.1 million as of September 30, 2025. Unpaid claims declined to $140.5 million from $156.4 million at year‑end, reflecting faster claim processing. Stockholders’ equity was $340.9 million. The company also recognized fair value gains tied to a remeasured private equity investment and realized gains on warrant liquidations, recorded in other income.
Class A shares outstanding were 421.8 million and Class B 92.4 million as of September 30, 2025, with treasury stock increasing due to repurchases and tax withholdings on equity awards.
Clover Health Investments (CLOV): insider transaction disclosed. Officer Jamie L. Reynoso (CEO, Medicare Advantage) sold 30,385 shares of Class A common stock at a weighted average price of $3.58 on November 4, 2025, pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
Following the sale, Reynoso beneficially owned 2,793,411 shares directly. The sale was executed in multiple trades at prices ranging from $3.49 to $3.67, and the reporting person undertakes to provide detailed trade breakdowns upon request.
Clover Health Investments (CLOV) disclosed a Form 4 for an officer (CEO of Home Care) showing tax-withholding transactions tied to RSU vesting. On 10/31/2025, the company automatically withheld 86,610 and 25,081 Class A shares at $3.53 per share to cover taxes as restricted stock units vested.
The filing notes these were tied to the final 50% of earned performance-based RSUs from an award dated October 31, 2023, and the final 12.5% of another RSU tranche vesting the same day. Following these transactions, the reporting person directly beneficially owned 2,228,583 Class A shares.
Clover Health Investments (CLOV) disclosed a Form 4 for officer Karen M. Soares (General Counsel & Secretary) showing tax-withholding transactions tied to RSU vesting. On 10/31/2025, two Code F entries were reported: 131,521 shares of Class A common stock and 38,086 shares were automatically withheld at a price of $3.53 per share to cover taxes.
The withholding related to performance-based RSUs granted on 10/31/2023, with one-half of earned units settled on 09/13/2024 and the remaining half vesting on 10/31/2025. An additional tranche representing the final 12.5% of RSUs from the same grant also vested on 10/31/2025. Following these transactions, Soares directly beneficially owned 1,236,228 Class A shares.
Clover Health (CLOV) reported insider activity by its officer (CEO, Medicare Advantage), Jamie L. Reynoso. On 10/31/2025, two transactions with code F reflected shares of Class A common stock automatically withheld to cover taxes upon RSU vesting: 101,917 shares related to performance-based RSUs and 29,513 shares related to time-based RSUs, each at $3.53.
Following these withholdings, the reporting person directly beneficially owned 2,823,796 shares. These entries reflect tax withholding tied to previously awarded RSUs and do not represent open-market sales.
Clover Health Investments (CLOV) insider filing: Officer Conrad Wai reported tax-withholding transactions tied to RSU vesting. On 10/31/2025, 96,448 shares of Class A common stock were withheld at $3.53 per share to satisfy taxes for the final 50% of earned performance-based RSUs from an award dated 10/31/2023. On the same date, 27,930 shares were withheld at $3.53 due to vesting of the final 12.5% of time-based RSUs.
Following these transactions, the reporting person beneficially owned 1,150,085 Class A shares directly. In addition, 1,610,482 shares were held indirectly by a family trust for which the reporting person serves as co-trustee. The filing identifies the reporting person as an officer (CEO, Counterpart Health).
Clover Health Investments, Corp. furnished an 8-K stating it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced.
Clover Health (CLOV) reported an insider equity transaction by its Chief Financial Officer. On October 29, 2025, 217,382 shares of Class A common stock were automatically withheld at $3.64 per share to cover taxes upon the vesting of a portion of previously granted RSUs.
The vesting represented 6.25% of the original time‑based RSU grant made on April 29, 2024. Following the transaction, the reporting person directly beneficially owns 5,915,209 shares. The remaining RSUs are scheduled to vest in equal quarterly installments through April 29, 2028, subject to continued service.
Clover Health Investments (CLOV) announced that Chelsea Clinton resigned from its Board of Directors and its Talent and Compensation and Nominating and Corporate Governance Committees, effective October 31, 2025. The company states her decision was not due to any disagreement regarding operations, policies, or practices.
The Board’s authorized size remains nine directors, and it will continue to operate with two vacant seats following her departure. The Board intends to fill the vacancy as soon as practicable.
Clover Health (CLOV) reported an insider transaction by its CEO, Medicare Advantage, Jamie L. Reynoso. On 10/17/2025, Reynoso sold 16,514 Class A shares in open market transactions at a $2.69 weighted average price, with trade prices ranging from $2.65 to $2.72. The sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025.
Following the sale, Reynoso beneficially owns 2,955,226 shares, held directly.